The latest update is out from Clinuvel Pharmaceuticals Limited ( (AU:CUV) ).
CLINUVEL Pharmaceuticals announced that CEO Dr. Philippe Wolgen will temporarily step down from his full duties to address an acute medical condition, with COO Lachlan Hay stepping in as Acting CEO. The company assures stakeholders that operations will continue smoothly during Dr. Wolgen’s absence, reflecting confidence in the executive team’s ability to maintain business continuity and achieve the company’s objectives.
More about Clinuvel Pharmaceuticals Limited
CLINUVEL Pharmaceuticals Limited is a global specialty pharmaceutical group headquartered in Melbourne, Australia. The company focuses on developing and commercializing treatments for genetic, metabolic, systemic, and life-threatening acute disorders, with a particular emphasis on photomedicine and melanocortin peptides. CLINUVEL’s lead therapy, SCENESSE®, is approved for use in several countries as a systemic photoprotective drug for patients with erythropoietic protoporphyria (EPP).
YTD Price Performance: -5.56%
Average Trading Volume: 479
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $365.5M
Learn more about CUV stock on TipRanks’ Stock Analysis page.